We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

20 hedge funds and large institutions have $59.2M invested in KalVista Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

15% more capital invested

Capital invested by funds: $51.4M → $59.2M (+$7.78M)

4.31% more ownership

Funds ownership: 73.83% → 78.14% (+4.3%)

0% more funds holding

Funds holding: 20 → 20 (0)

Holders
20
Holders Change
–
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
4
Increased
4
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.06M
2
EAM
Eventide Asset Management
Massachusetts
+$737K
3
ARTA
A.R.T. Advisors
New York
+$83.5K
4
BFM
Boothbay Fund Management
New York
+$40K
5
BlackRock
BlackRock
New York
+$25.7K

Top Sellers

Rank Fund Capital Flow
1
FQ
First Quadrant
California
-$14.3K
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.25K
3
Creative Planning
Creative Planning
Kansas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$22.7M – – –
SHI
2
SV Health Investors
Massachusetts
$20.1M – – –
RCM
3
RA Capital Management
Massachusetts
$4.62M – – –
IVM
4
InterWest Venture Management
California
$2.58M – – –
IBT
5
International Biotechnology Trust
United Kingdom
$2.52M – – –
VC
6
Vivo Capital
California
$2.35M – – –
VMI
7
VHCP Management II
New York
$1.64M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.41M +$1.06M +141,476 +360%
EAM
9
Eventide Asset Management
Massachusetts
$766K +$737K +98,100 New
BFM
10
Boothbay Fund Management
New York
$169K +$40K +5,319 +33%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$88K -$1.25K -167 -1%
ARTA
12
A.R.T. Advisors
New York
$86K +$83.5K +11,116 New
FQ
13
First Quadrant
California
$85K -$14.3K -1,900 -15%
BlackRock
14
BlackRock
New York
$27K +$25.7K +3,418 New
UBS Group
15
UBS Group
Switzerland
$18K +$10.5K +1,398 +154%
TRCT
16
Tower Research Capital (TRC)
New York
$6K +$3.32K +442 +168%
Manulife (Manufacturers Life Insurance)
17
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3K – – –
Morgan Stanley
18
Morgan Stanley
New York
$1K – – –
Creative Planning
19
Creative Planning
Kansas
– -$1K -142 Closed
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
– +$8 +1 New

KALV Hedge Fund Activity: Q1 2017 in Review

20 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2017, worth a combined $59.2M — up 15% from $51.4M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new KALV positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.06M. The largest seller was First Quadrant, cutting an estimated $14.3K.

  • 20 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $59.2M of KalVista Pharmaceuticals stock for Q1 2017, up 15% quarter-over-quarter.
  • 4 funds opened new KalVista Pharmaceuticals positions in Q1 2017 and 1 closed out, a net change of +3 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2017 was Vanguard Group, an estimated $1.06M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2017 was First Quadrant, an estimated $14.3K sold.

Based on aggregated 13F filings for Q1 2017.